CanCure, LLC
dba CanZx Biotherapeutics

Tel: (206) 353-7538
cancurellc@canzxbio.com

First-in-Class Cancer Immunotherapeutics


Empower your own immune system to fight cancer

News Highlights

CanCure Leading technology CuraB-10 (B10G5) was featured in SITC (Society of Immunotherapy of Cancer) annual meeting
Daily highlights on Nov. 12th, 2016 whcih was held in National Harbor, MD.

Read the Article

CanCure is an anticancer drug development company that aims to mature and advance our current proprietary immunotherapeutic antibody platforms into clinic for cancer treatment. CanCure is taking the First-in-Class cancer immunotherapeutic antibody CuraB-10 into clinic.

Managment

Jennifer Wu, PhD. Founder, CSO, and Intrim CEO
Dr. Wu is the inventor of CuraB-10. She brings her expertise and vision in Onco-Immunology and her prior experience with Biotechnology Development. Dr. Wu is currently a Professor at the Medical University of South Carolina (MUSC) and Hollings Cancer Center. Dr. Wu was tenured at the Univesrity of Washington prior to joing MUSC.  Dr. Wu holds a PhD from University of British Columbia (UBC) Canada and completed post-doctiral training at the Fred Hutchinson Cancer Research Center. Dr. Wu has served as Scientific Liason and Section Director at several leading Biotech Companies. Dr. Wu has successfully secured funds from NIH in completion the early development milestones of CuraB-10.

Craig W. Philips. BS, MBA
Craig brings his 25 years of BioPharma leadership experience including Executive VP of Commercial operation and President of Kineta Inc, President of Cell therapeutics Inc, VP and General Manager of Bayer Oncology, Berlex Biosciences etc. Mr. Philips Holds a B.S. and a MBA from the Ohio State University.

Eddie Xing MD, Clinical Development Consultant

Eddie brings his more than 30 years of medical experience into Drug Development. His most recent work features the study designs, protocol developments and implementations, and medical monitoring of global clinical trials of a new anti-PD1 antibody (licensed by Incyte). Eddie completed his medical education and postgraduate training in China, and moved to the United States in 1991 to pursue clinical and medical research opportunities. He is certified with USMLE-ECFMG in the United States.



Advisory Board

Norm M Greenberg, PhD

Dr. Greenberg  is a Senior VP of Checkmate Pharmaceuticals. Prior to that, he has served as Senor VP of Research at MedImmune (Astrazeneca) and Senior Director of Oncology at Pfizer, Professor at Fred Hutchinson Cancer Research center. Dr. Green has over 25 years professional experience as a scientist, drug researcher and developer and I have delivered innovative research programs in academia and industry, including important leading edge therapies includes immunotherapy, immuno-oncology (ex: 41BB, CTLA4, PDL1, OX40), tumor targeted therapies and antibody drug conjugates.

John Vournakis. PhD

Dr. Vournakis is the Vice President of Research and Development and co-founder of Marine Polymer Technologies, Inc. before joining Marie Polymer InC, Dr. Vournakis has been tenured as Professor at Dartmouth College where he founded the Molecular Genetics Center at Dartmouth. He is a co-founder of Marine Polymer Technologies, Inc., which has been in existence since 1992. Dr. Vournakis has been a Science Advisor to and Director of several biotechnology companies.  Dr. Vournakis received a PhD degree from the Cornell University Department of Chemistry in Physical Biochemistry in 1968. He was trained as a post-doctoral and research associate at MIT and Harvard Universities.

Cassein Yee, MD

Dr. Yee is a Professor of Melanoma Medical Oncology, Division of Cancer Medicine and Director of Solid Tumor Cell Therapy at the Center for Cancer Immunology Research of The University of Texas MD Anderson Cancer Center. Dr. Yee has pioneered many innovative technologies in enhancing cell-based cancer immunotherapy. He is a member of the SU2C Scientific Research Team. Dr. Yee received his medical degree from the University of Manitoba in Canada and trained as a research fellow at the Ontario Cancer Institute in Toronto before continuing his medical residency at Stanford University and a fellowship in medical oncology at the University of Washington and the Fred Hutchinson Cancer Research Center.